Complement as an endogenous adjuvant for dendritic cell-mediated induction of retrovirus-specific CTLs

PLoS Pathogens

Volumn 6, Issue 4, 2010, Pages

  Banki Zoltan ^a   Posch, Wilfried ^a   Ejaz, Asim ^a   Oberhauser, Verena ^a   Willey, Suzanne ^b   Gassner, Christoph ^c   Stoiber, Heribert ^a   Dittmer, Ulf ^d   Dierich, Manfred P ^a   Hasenkrug, Kim J ^e   Wilflingseder, Doris ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c Central Institute for Blood Transfusion and Immunological Department   (Austria)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; GAMMA INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTIVIRAL ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; FRIED VIRUS; FRIED VIRUS INFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE DIFFERENTIATION; MOUSE; NONHUMAN; OPSONIZATION; RNA VIRUS; T LYMPHOCYTE ACTIVATION; VIRUS INFECTION;

FRIEND MURINE LEUKEMIA VIRUS;

EID: 77954082267     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1000891     Document Type: Article

References (41)

1. Pantaleo G, Demarest JF, Soudeyns H, Graziosi C, Denis F, et al. (1994) Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV. Nature 370: 463-467.
2. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB (1994) Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 68: 6103-6110.
3. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, et al. (1994) Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68: 4650-4655.
4. McMichael AJ, Rowland-Jones SL (2001) Cellular immune responses to HIV. Nature 410: 980-987.
5. Deeks SG, Walker BD (2007) Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27: 406-416.
6. Betts MR, Gray CM, Cox JH, Ferrari G (2006) Antigen-specific T-cell-mediated immunity after HIV-1 infection: implications for vaccine control of HIV development. Expert Rev Vaccines 5: 505-516.
7. Mehlhop E, Whitby K, Oliphant T, Marri A, Engle M, Diamond MS (2005) Complement activation is required for induction of a protective antibody response against West Nile virus infection. J Virol 79: 7466-7477.
8. Da Costa XJ, Brockman MA, Alicot E, Ma M, Fischer MB, et al. (1999) Humoral response to herpes simplex virus is complement-dependent. Proc Natl Acad Sci U S A 96: 12708-12712.
9. Verschoor A, Brockman MA, Knipe DM, Carroll MC (2001) Cutting edge: myeloid complement C3 enhances the humoral response to peripheral viral infection. J Immunol 167: 2446-2451.
10. Kopf M, Abel B, Gallimore A, Carroll M, Bachmann MF (2002) Complement component C3 promotes T cell priming and lung migration to control acute influenza virus infection. Nat Med 8: 373-378.
11. Suresh M, Molina H, Salvato MS, Mastellos D, Lambris JD, Sandor M (2003) Complement component 3 is required for optimal expansion of CD8 T cells during a systemic viral infection. J Immunol 170: 788-794.
12. Mehlhop E, Diamond MS (2006) Protective immune responses against West Nile Virus are primed by distinct complement activation pathways. J Exp Med 203: 1371-1381.
13. Stager S, Alexander J, Kirby AC, Botto M, Rooijen NV, et al. (2003) Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T cell responses. Nat Med 9: 1287-1292.
14. Wilflingseder D, Banki Z, Garcia E, Pruenster M, Pfister G, et al. (2007) IgG opsonization of HIV impedes provirus formation in and infection of dendritic cells and subsequent long-term transfer to T cells. J Immunol 178: 7840-7848.
15. Stoiber H, Soederholm A, Wilflingseder D, Gusenbauer S, Hildgartner A, et al. (2008) Complement and antibodies: a dangerous liaison in HIV infection? Vaccine 8: I79-185.
16. Pruenster M, Wilflingseder D, Bánki Z, Ammann CG, Muellauer B, et al. (2005) C-type lectin-independent interaction of complement opsonized HIV with monocyte-derived dendritic cells. Eur J Immunol 35: 2691-2698.
17. Hasenkrug KJ, Dittmer U (2007) Immune control and prevention of chronic Friend retrovirus infection. Front Biosci 12: 1544-1551.
18. Dittmer U, He H, Messer RJ, Schimmer S, Olbrich AR, Ohlen C, Greenberg PD, Stromnes IM, Iwashiro M, Sakaguchi S, Evans LH, Peterson KE, et al. (2004) Functional impairment of CD8(+) T cells by regulatory T cells during persistent retroviral infection. Immunity 20: 293-303.
19. Zelinskyy G, Kraft AR, Schimmer S, Arndt T, Dittmer U (2006) Kinetics of CD8+ effector T cell responses and induced CD4+ regulatory T cell responses during Friend retrovirus infection. Eur J Immunol 36: 2658-2670.
20. + T cells by a flow cytometric assay for degranulation. J Immunol Methods 281: 65-78.
21. Agnellini P, Wolint P, Rehr M, Cahenzli J, Karrer U, et al. (2007) Impaired NFAT nuclear translocation results in split exhaustion of virus-specific CD8+ T cell functions during chronic viral infection. Proc Natl Acad Sci U S A 104: 4565-4570.
22. Balkow S, Krux F, Loser K, Becker JU, Grabbe S, Dittmer U (2007) Friend retrovirus infection of myeloid dendritic cells impairs maturation, prolongs contact to naive T cells, and favors expansion of regulatory T cells. Blood 110: 3949-3958.
23. Hasenkrug KJ (1999) Lymphocyte deficiencies increase susceptibility to friend virus-induced erythroleukemia in Fv-2 genetically resistant mice. J Virol 73: 6468-6473.
24. + T Cell Effector Activity Is Dictated by Cognate Peptide Concentration. J Immunol 172: 6407-6417.
25. Jung S, Unutmaz D, Wong P, Sano G, De los Santos K, et al. (2002) In vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+) T cells by exogenous cell-associated antigens. Immunity 17: 211-220.
26. Probst HC, van den Broek M (2005) Priming of CTLs by lymphocytic choriomeningitis virus depends on dendritic cells. J Immunol 174: 3920-3924.
27. Browne EP, Littman DR (2009) Myd88 is required for an antibody response to retroviral infection. PLoS Pathog 5: e1000298.
28. Messer RJ, Dittmer U, Peterson KE, Hasenkrug KJ (2004) Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection. Proc Natl Acad Sci U S A 101(33): 12260-5.
29. Castro FV, Tutt AL, White AL, Teeling JL, James S, et al. (2008) CD11c provides an effective immunotarget for the generation of both CD4 and CD8 T cell responses. Eur J Immunol 38: 2263-2273.
30. Saron MF, Fayolle C, Sebo P, Ladant D, Ullmann A, et al. (1997) Anti-viral protection conferred by recombinant adenylate cyclase toxins from Bordetella pertussis carrying a CD8+ T cell epitope from lymphocytic choriomeningitis virus. Proc Natl Acad Sci U S A 94: 3314-3319.
31. Guermonprez P, Khelef N, Blouin E, Rieu P, Ricciardi-Castagnoli P, et al. (2001) The adenylate cyclase toxin of Bordetella pertussis binds to target cells via the alpha(M)beta(2) integrin (CD11b/CD18). J Exp Med 193: 1035-1044.
32. Simsova M, Sebo P, Leclerc C (2004) The adenylate cyclase toxin from Bordetella pertussis-a novel promising vehicle for antigen delivery to dendritic cells. Int J Med Microbiol 293: 571-576.
33. Behrens EM, Sriram U, Shivers DK, Gallucci M, Ma Z, et al. (2007) Complement receptor 3 ligation of dendritic cells suppresses their stimulatory capacity. J Immunol 178: 6268-6279.
34. Skoberne M, Somersan S, Almodovar W, Truong T, Petrova K, Henson PM, Bhardwaj N (2006) The apoptotic-cell receptor CR3, but not alphavbeta5, is a regulator of human dendritic-cell immunostimulatory function. Blood 108: 947-955.
35. Thornton BP, Větvicka V, Ross GD (1994) Natural antibody and complementmediated antigen processing and presentation by B lymphocytes. J Immunol 1994 Feb 15;152(4): 1727-37.
36. Liu F, Mboudjeka I, Shen S, Chou TH, Wang S, Ross TM, Lu S (2004) Independent but not synergistic enhancement to the immunogenicity of DNA vaccine expressing HIV-1 gp120 glycoprotein by codon optimization and C3d fusion in a mouse model. Vaccine 22: 1764-1772.
37. Ohlén C, Kalos M, Cheng LE, Shur AC, Hong DJ, et al. (2002) CD8(+) T cell tolerance to a tumor-associated antigen is maintained at the level of expansion rather than effector function. J Exp Med 195: 1407-1418.
38. Chen W, Qin H, Chesebro B, Cheever MA (1996) Identification of a gagencoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors. J Virol 70: 7773-7782.
39. Bánki Z, Kacani L, Rusert P, Pruenster M, Wilflingseder D, et al. (2005) Complement dependent trapping of infectious HIV in human lymphoid tissues. AIDS 19: 481-486.
40. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, et al. (1992) Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176: 1693-1702.
41. Robertson MN, Miyazawa M, Mori S, Caughey B, Evans LH, et al. (1991) Production of monoclonal antibodies reactive with a denatured form of the Friend murine leukemia virus gp70 envelope protein: use in a focal infectivity assay, immunohistochemical studies, electron microscopy and western blotting. J Virol Methods 34: 255-271.